Navigation Links
Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP,,Rheumatoid Arthritis and Lymphoma

very well tolerated in the first dose group. To expedite patient recruitment, Rigel has added additional clinical sites that have significant experience in RA clinical trials. Rigel expects to receive results from the completed clinical trial in the second half of 2007.

Rigel today announced the enrollment of patients in a multi-center, Phase 2 clinical trial to evaluate the safety and efficacy of R788 for the treatment of patients with B-cell lymphoma. Approximately 80% of patients with non- Hodgkin's lymphoma have the B-cell variety, which is characterized by an over- expression of B-cell receptors and the proliferation of B-cells. Research has shown that R788 effectively interrupts the growth of B-cells and signaling proteins that contribute to the survival of these tumors.

The open label clinical trial is expected to enroll a total of approximately 60 patients at 10 major cancer treatment centers in the U.S. and will focus on refractory diffuse large, follicular and mantle B-cell lymphomas. The primary efficacy endpoint will be overall response rate according to standard criteria. Secondary efficacy, safety and pharmacodynamic endpoints, as well as the role of syk activation in predicting responses, will also be measured. Depending on enrollment, results of the clinical trial are expected in 2008.

R788 is a novel, oral syk kinase inhibitor that blocks the activation of mast cells, macrophages and B-cells that promote swelling, inflammatory responses and tissue damage. These activities derive from syk kinase's pivotal role in mediating immunoglobulin signaling inside cells. It is currently being evaluated in two Phase 2 studies with respect to RA and ITP, and enrollment in an additional Phase 2 clinical trial in B-cell lymphoma has commenced. Phase 1 trial results demonstrated that R788 was well tolerated and showed good pharmaceutical properties when administered both alone and, with respect to the treatment of patients with RA, in combinat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present New Research Programs at AACR Meeting
2. Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity
3. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
4. XTL Provides Update on Phase I Clinical Trial of XTL-2125
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
9. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
(Date:2/26/2015)... Feb. 26, 2015  IRIDEX Corporation (NASDAQ: IRIX ... and full year 2014 financial results after the market closes ... the release, the Company will host a conference call with ... Thursday, March 5, 2015 to discuss the ... Interested parties may access the live conference call via telephone ...
(Date:2/26/2015)... , Feb. 26, 2015  Mail-service and ... consumers, employers and government health plans $23.3 ... released by the Pharmaceutical Care Management Association (PCMA). ... drugs offers one of the easiest ways to ... Mark Merritt . "Policymakers should resist efforts ...
(Date:2/26/2015)... -- Every year many millions of donations are obtained ... year after year doctors and the medical profession continue ... to determine the status of heart health in all ... though that technology is over 100 years old, ... (while most patients do not know) that EKG,s, in ...
Breaking Medicine Technology:IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2National Heart Health Month In February 2
... as Marker of,Treatment Success -, SAN FRANCISCO, ... presented at the 59th Annual Meeting of,the American ... shows that,PEGASYS(R) (peginterferon alfa-2a) treatment regimens result in ... patients as,compared to regimens with another pegylated interferon.(1), ...
... Denmark, October 31 , - DoctorConsult in ... Improve Clinician Decision Making and Health Care Business,Performance, ... and more than a,century of experience as a ... provide interactive clinical reference and clinical decision,support (CDS) ...
Cached Medicine Technology:New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7Elsevier is Expanding eClinical Solutions in Europe 2Elsevier is Expanding eClinical Solutions in Europe 3
(Date:2/27/2015)... February 27, 2015 On February 24 2015, ... Liquid Botox ,” that details the development of RT001, ... working its way through FDA trials. For those afraid of ... is very attractive. Of course, if the drug ultimately gets ... a physician’s office. (see: goo.gl/PQvQwk) , “As the article notes, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Winter is here, ... on human skin, exposure to snow and ice can be ... also hurt dogs’ paws. The Puppy Store is ready to ... keep their dogs safe in the winter time. , Ice ... vomiting, diarrhea and other symptoms. Ingestion of ice melt products ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Victorian Hotel ... deals for couples who wanted to spend the auspicious ... opportunity to get a jump on Valentine’s Day with ... stay in one of their luxurious rooms. , ... 13, inviting guests for a mouthwatering 3 course meal ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Mediaplanet today ... “Blood Health,” a campaign that aims to bring blood ... health care conversation. The stories in this edition go ... world of clinical care, hard-hitting advocacy, research and technological ... , According the American Cancer Society, approximately every ...
(Date:2/27/2015)... February 27, 2015 The Nashville ... announced a scholarship for rising freshmen undergraduate students. , ... periodontist office specializing in many periodontal procedures such as ... of gum disease . In honor of their ... scholarship for eligible rising freshmen undergraduate students. , ...
Breaking Medicine News(10 mins):Health News:Is Topical Botox the Next Big Thing? 2Health News:The Puppy Store Helps Dogs Prepare for Harsh Winter Conditions 2Health News:Victorian Hotel Celebrated Valentine’s Day in 2015 With Unique Overnight Deal 2Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2Health News:Nashville Periodontist Office AIOH Announces 2015 Scholarship 2
... HighPoint Solutions LLC,a premier provider of business-driven IT ... one of the top three pharmaceutical companies in ... Scorecard solution. This,project will provide the pharmaceutical leader ... in a complete view of,its customers and related ...
... day if possible. At least this is the conclusion suggested ... the University of Bonn ( Transplantation Proceedings, vol. 40, ... a further operation more than twice as often as other ... is higher with operations taking place at night. The reason ...
... Provides consistent information and streamlines service delivery to ... ... Lagan, a provider of enterprise,case management solutions that streamline the delivery ... Lagan Human Services(TM) to support the county,s e-Government,initiative for its Human ...
... on Achieving Your Personal Best and Discuss Why They Talked ... ... 15 Five-time gold medalist,Nadia Comaneci, and nine-time gold medalist, Mark ... BOTOX(R) Cosmetic (Botulinum Toxin,Type A), to launch a new consumer education ...
... Group,(Amex: QGP ) (http://www.QuantumMD.com ) has ... a third party administrator (TPA) with the state ... Renaissance,Administrative Services, Inc. (RASI), to provide administrative claims,processing ... A TPA provides an outsourced solution to companies ...
... To Make Medical Pharmacy Claims Processing More Efficient, ... the signing of,a new three-year contract with Blue ... providers to submit claims for complex services, such ... ACM,s proprietary,e-Precision claims(SM) technology will streamline the claims ...
Cached Medicine News:Health News:HighPoint Solutions to Develop Contract Analytics Solution for a Top Three Pharmaceutical Company 2Health News:Kidney transplants less successful at night 2Health News:Hennepin County, Minnesota Selects Lagan Human Services(TM) to Support Human Services and Public Health Department e-Government Initiative 2Health News:Hennepin County, Minnesota Selects Lagan Human Services(TM) to Support Human Services and Public Health Department e-Government Initiative 3Health News:Legendary Sports Icons, Nadia Comaneci and Mark Spitz, Support Your Personal Best Public Education Campaign 2Health News:Legendary Sports Icons, Nadia Comaneci and Mark Spitz, Support Your Personal Best Public Education Campaign 3Health News:Legendary Sports Icons, Nadia Comaneci and Mark Spitz, Support Your Personal Best Public Education Campaign 4Health News:Legendary Sports Icons, Nadia Comaneci and Mark Spitz, Support Your Personal Best Public Education Campaign 5Health News:Legendary Sports Icons, Nadia Comaneci and Mark Spitz, Support Your Personal Best Public Education Campaign 6Health News:Legendary Sports Icons, Nadia Comaneci and Mark Spitz, Support Your Personal Best Public Education Campaign 7Health News:The Quantum Group Files TPA Application 2Health News:The Quantum Group Files TPA Application 3Health News:Blue Shield of California and ACM Sign New 3-Year Agreement 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: